Centiva Capital, LP Arbutus Biopharma Corp Put Options Transaction History
Centiva Capital, LP
- $5.63 Billion
- Q2 2024
Put Options
2 transactions
Others Institutions Holding ABUS
# of Institutions
137Shares Held
95.4MCall Options Held
3.44MPut Options Held
377K-
Morgan Stanley New York, NY21MShares$80.3 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY12.9MShares$49.3 Million30.08% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$44.2 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY8.57MShares$32.8 Million10.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.02MShares$26.9 Million0.0% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $574M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...